Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating ...

MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD ...

Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment ...

The biotech company extends its Phase I trial (NCT06252220) of DA-1726 to eight weeks following encouraging early efficacy, ...

Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...

Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 -- Cash runway into the second quarter of 2026 - ...

Alphamab’s bispecific ADC enters the IND pipeline with promise. JSKN022 is an innovative bispecific ADC developed in-house ...

YourChoice Therapeutics, working with Quotient Sciences and Incyte, reports that single oral doses of the investigational non ...

Researchers conducted a retrospective study published in July 2025 issue of Journal of Hematology & Oncology to examine the ...

Intervention/Treatment: The study tested PF-07275315, an experimental drug administered as a single intravenous infusion. The purpose was to evaluate its safety profile and how it behaves in the body ...